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Familial, hemodynamic and metabolic factors in the predisposition to
diabetic kidney disease. Proteinuric diabetic patients have an increased
risk of cardiovascular disease and almost always have hypertension. In
the early stages of diabetic renal disease (microalbuminuria) when renal
function is well preserved, systemic arterial blood pressure is already
elevated compared to insulin-dependent diabetic patients without mi-
croalbuminuria. Prospective studies have shown that normoalbumin-
uric patients who progress to microalbuminuria have higher blood
pressures (albeit within the normal range) than those who persistently
remain normoalbuminuric. Parents of insulin-dependent diabetic pa-
tients with nephropathy have a higher prevalence of hypertension and
cardiovascular disease compared to those of patients without nephrop-
athy. Moreover, diabetic nephropathy clusters within families. Eryth-
rocyte sodium-lithium countertransport activity, the most consistent
marker for essential hypertension and its cardiorenal complications, is
elevated in diabetic patients with nephropathy and in their non-diabetic
parents. These data suggest that a familial predisposition to arterial
hypertension and cardiovascular disease increases the risk for the
development of nephropathy and its associated cardiovascular compli-
cations in insulin-dependent diabetes, Arterial hypertension is a state of
insulin resistance and diabetic patients susceptible to nephropathy have
been found to be less insulin sensitive. Preventive strategies of diabetic
kidney disease in the future will have to take into account its metabolic
hemodynamic and familial basis.
Nephropathy occurs only in a subset of approximately 30% of
insulin-dependent diabetic patients, having its highest incidence
in the second decade of diabetes [1, 2]. In non-insulin-depen-
dent diabetes the cumulative incidence of proteinuria after 20
years of the disease varies between 25% in Caucasian popula-
tions to approximately 50% m other ethnic groups.
Proteinuria
Persistent clinical proteinuna is closely associated with the
presence of hypertension in IDDM patients [1]. In NIDDM
patients the risk of developing clinical proteinuria is increased
more than twofold in patients with blood pressure >165/95 mm
Hg compared to those with lower blood pressure after adjusting
for age, sex and duration of diabetes [3]. Moreover, in both
insulin-dependent and non-insulin-dependent diabetes, the age
adjusted total mortality rate is greatly increased in those pa-
tients with proteinuna or hypertension [4, 51.
In insulin-dependent diabetes the development of clinical
proteinuria occurs through a continuous progressive rise of
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albumin excretion rate (AER) from the normal (AER <30 mg/24
hr) and across the microalbuminuric range (AER 30 to 300
mg/24 hr). Once clinical proteinuria is established, renal func-
tion declines in a relentless fashion and systemic arterial blood
pressure rises concomitantly [6]. However, prior to the devel-
opment of clinical proteinuria systolic and diastolic blood
pressure levels are already significantly elevated in patients
with microalbuminuria compared to those of patients with
normoalbuminuria [7, 8]. In this spectrum of AER, changes in
AER over time have been shown to be significantly positively
correlated with changes in mean blood pressure [81.
Renal function is well preserved at the stage of microalbu-
minuria and therefore, renal failure is unlikely to be the cause of
the observed rise in systemic blood pressure. In comparative
studies of matched insulin-dependent diabetic patients with or
without microalbuminuria, the presence of microalbuminuria
has been shown to be associated not only with a rise in systemic
blood pressure but also with poorer blood glucose control [9],
lipid abnormalities [10, 111, and more severe pathological
changes within the kidney [12]. Long-term longitudinal studies
have shown that microalbuminuria is the strongest independent
predictor of the development of clinical nephropathy in insulin-
dependent diabetes [13, 14] and of early mortality and cardio-
vascular disease in non-insulin dependent diabetes [15]. A
recent prospective study in non-insulin-dependent diabetic pa-
tients demonstrated that 80% of the total mortality in the
microalbuminunc group was due to cardiovascular causes [5].
Transition to microalbuminuria
Studies in normoalbuminuric patients may assist us in under-
standing the factors which determine in a subset of patients the
transition from normal albumin excretion rate to microalbumin-
uria. Two longitudinal studies have explored this issue, Mathie-
sen et al [16] followed up 205 normoalbuminuric, normotensive
insulin-dependent diabetic patients for 60 months. Seven pro-
gressed to persistent microalbuminuria. Compared to patients
who did not progress and remained normoalbuminuric, initial
AER was significantly greater and glycosylated hemoglobin
higher in the group of progressors. However, baseline blood
pressure was similar and rose in the progressors only after
microalbuminuna (defined as AER> 20 pgImin) had developed
for approximately two years. These findings suggested that
blood glucose control and the initial level of albumin excretion
rate are the main determinants of microalbuminuria and that
microalbuminuna precedes and possibly causes the rise in
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Table 1. Predictors of development of microalbuminuria in IDDM
patients
Variables coefficients P value
AER 4.10 0.012
MBP 0.23 0.003
Smoking 2.13 0.049
blood pressure. Blood pressure data in this study have to be
interpreted with caution in that arterial pressure was only
measured once a year to the nearest 5 mm Hg by different
observers, and the variation in these measurements was signif-
icantly greater than that of the AER which was measured four
times a year by a sensitive immunoassay. This lack of precision
in blood pressure measurement could have missed changes of
between 4 and 5 mm Hg.
In a prospective study by the Microalbuminuric Collabora-
tive Study Group (MCS) [17], the factors affecting the develop-
ment of persistent microalbuminuria was investigated in 137
non-microalbuminuric non-hypertensive insulin-dependent dia-
betic patients, who were observed for at least four years.
Eleven patients progressed to persistent microalbuminuria and
compared to non-progressors showed at baseline a significantly
higher mean SD mean blood pressure 101 2.4 versus 90
0.9 mm Hg (P < 0.05), geometric mean (95% CI) albumin
excretion rate 14.8 (12.4 to 17.2) versus 4.3 (2.1 to 6.4) /Lglmin
(P < 0.05) and glycosylated hemoglobin 10.4 0.6 versus 8.9
0.2% (P < 0.05). Blood pressure and glycosylated hemoglobin
levels remained significantly higher in the group of progressors
over the four-year observation period. Moreover, the patients
who progressed to microalbuminuria had a significantly greater
percentage of smokers. The cumulative incidence of microal-
buminuria was 8%. A stepwise logistic regression analysis
indicated that initial albumin excretion rate, blood pressure and
smoking were significant determinants of microalbuminuna
(Table 1). Glycosylated hemoglobin just missed conventional
significance (P < 0.06) and was excluded from the regression
model.
These two studies identify some common determinants of
microalbuminuria, namely albumin excretion rate and blood
glucose control, but differ in their findings concerning the role
of blood pressure. The MCS study clearly indicates that the rise
in blood pressure occurs concomitantly to that of albumin
excretion rate and that it does not require the development of
microalbuminuria. Indeed, a blood pressure rise is taking place
while albumin excretion is increasing within the normal range in
the group of progressors. Studies in insulin-dependent diabetic
patients with shorter duration of disease will be required to
understand the chronological relationship between the early
increases in albumin excretion rate and blood pressure in
normoalbuminuric patients progressing to microalbuminuria.
Two recent studies in NIDDM patients underscore the pri-
mary importance of early elevations in blood pressure. In a
study in Pima Indians [18], systematic measurements of blood
pressure were obtained in 356 subjects before the development
of diabetes. Arterial pressure values were then related to the
development of proteinuria measured as albumin/creatinine
ratio, after the onset of diabetes. It was found that the incidence
of proteinuria was threefold higher in the patients in the highest
tertile of prediabetic blood pressure. A five-year prospective
study of 39 Japanese patients with NIDDM and normoalbumi-
nuria demonstrated that age-adjusted mean arterial pressure
(98.2 3.4 vs. 87.3 2.4; P < 0.05) and frequency of
hypertension (72.7% vs. 17.4%; P < 0.01) were significantly
greater initially in the 11 patients who developed microalbumin-
uria compared to the 23 patients who remained normoalbumin-
uric [191. All these findings taken together strongly support the
view that pre-microalbuminuric evolutionary stages of diabetic
nephropathy are associated with an elevation of the systemic
arterial pressure. This early rise in systemic blood pressure
suggests that a predisposition to hypertension may be an
important feature in the genesis of nephropathy.
Familial factors
Evidence for genetic determinants in the development of
nephropathy has come from several sources. Familial clustering
of diabetic nephropathy was first reported by Seaquist et al [20]
and subsequently was confirmed by other workers [21]. The
factors responsible for this aggregation were, however, not
explored in these studies. Higher values of arterial pressure in
parents of insulin-dependent diabetic patients with proteinuria
than in parents of matched IDDM patients with normoalbumin-
uria were reported by Viberti et al [22] in a study in which blood
pressure was directly measured in a standardized manner. This
observation was confirmed by Krolewski et al [23] who, using
information collected by means of a questionnaire, reported a
significantly higher prevalence of arterial hypertension among
the parents of insulin-dependent diabetic patients with micro-
and macroalbuminuria. These studies, though not confirmed by
all authors [24], suggest that a family history of hypertension
confers an increased susceptibility to the development of pro-
teinuna in subgroups of insulin-dependent diabetic patients.
Further definition of the familial factors involved in the devel-
opment of diabetic nephropathy has come from the observation
that parents of insulin-dependent diabetic patients with protein-
uria have a significant excess of cardiovascular disease com-
pared to parents of insulin-dependent diabetic patients who did
not develop kidney disease. Earle et al [25] found that the
prevalence of cardiovascular disease was significantly greater
(31% vs. 14%; P < 0.01) and the frequency of cardiovascular
disease as a direct cause of death was also significantly higher
(40% vs. 22%; P < 0.03) in the parents of insulin-dependent
diabetic patients with nephropathy. In this group of parents, the
age- and sex-adjusted relative risk for cardiovascular disease
was 2.9; 95% CI 1.5 to 5.5 (P < 0.001). A history of cardiovas-
cular disease in both parents or in the father alone was
associated with an age, sex and duration of diabetes adjusted
increased risk of nephropathy in the diabetic offspring of
approximately 10- and threefold, respectively (Fig. 1). Among
the diabetic patients with nephropathy a positive family history
of cardiovascular disease was significantly more frequent in
those who had suffered a cardiovascular event (odds ratio 6.2,
95% CI 2 to 19; P < 0.005). This study indicated that in
insulin-dependent diabetes, a predisposition to cardiovascular
disease increases the risk of nephropathy and the risk of
cardiovascular disease in those with nephropathy, and sug-
gested that both disorders may share similar pathogenetic
processes which may have a genetic or shared environmental
basis.
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Sodium-lithium countertransport and insulin sensitivity
An elevated erythrocyte sodium-lithium countertransport ac-
tivity (Na/Li-CT) is the most consistent marker for essential
hypertension [26] and its interindividual variability is largely
under genetic control [27, 28]. Furthermore, raised Na/
Li-CT has been found to be associated with some of the renal
and cardiovascular complications of arterial hypertension [29-.
31]. In insulin-dependent diabetes, raised NaILi-CT rates
have been found in patients with both micro- and macroalbu-
minuria by several [32, 33] though not all authors [34]. Parents
of proteinuric insulin-dependent diabetic patients with high
Na/Li-CT have also been found to have elevated values in
one study [35], though not in another [24], confirming the high
heritability of the rates of Na/Li-CT described in the general
population and in subjects with arterial hypertension [36].
In a study of 185 consecutive insulin-dependent diabetic
patients [37] the prevalence of supranormal Na/Li-CT activ-
ity (that is, >0.40 mmollliter RBC X hr) was found to be 21.5,
42.8 and 51.7 percent in normoalbuminuric, microalbuminuric
and proteinuric patients, respectively, a highly significant dif-
ference (P < 0.005 by ANOVA). The percentage of patients
with proteinuria (micro- and macroalbuminuria) significantly
increased with increasing quartiles of the Na/Li-CT distribu-
tion. Sodium-lithium countertransport activity significantly cor-
related with albumin excretion rate (r = 0.38, P < 0.001) and
mean arterial pressure (r = 0.37, P < 0.001), and a raised
activity conferred a fourfold risk of developing proteinuria. In a
multiple logistic regression analysis, Na/Li-CT emerged as
the most important determinant of proteinuria followed by
duration of diabetes, mean blood pressure and glycosylated
hemoglobin. The frequency of patients with proteinuria was
greatly increased in the category of patients with Na/Li-CT
above the upper limit of normal who also had glycosylated
hemoglobin values above the median (Fig. 2). This link between
Na/Li-CT on the one hand, and higher arterial pressure and
worse blood glucose control, both risk factors for macro- and
microvascular disease, on the other, may find an explanation in
an altered sensitivity to insulin. Lopes de Faria et al [38] studied
two groups of normotensive, non-proteinuric insulin-dependent
diabetic patients with normal and elevated Na/Li-CT. Using
a hyperinsulinemic euglycemic clamp technique these authors
demonstrated greater resistance to peripheral insulin action in
<0.41 >0.41 Na/LiCT
mmol/fiter
_________ _________ ABC x hr
Above median HbA1 (%)
Fig. 2. Relationship of the frequency of IDDM patients with nephrop-
athy (hatched bars) and without nephropathy (open bars) above and
below the upper limit of normal of sodium-lithium countertransport
activity (0.41 mmol/liter rbc X hr) according to the distribution of
glycosylated hemoglobin (HbA1),
the group with high Na/Li-CT. This study which has recently
been confirmed [39] was the first to give insights into a possible
metabolic basis for the association of an altered cell membrane
ion transport system, predictive of cardiovascular risk, and
other risk factors for vascular complications. Hyperinsulinemia
and insulin resistance have been implicated in the risk of
cardiovascular disease in the general population [40]. Strategies
for the prevention of diabetic kidney disease must in the future
take in consideration the hemodynamic, metabolic and familial
bases of this complication of diabetes mellitus.
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